Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

Everolimus versus alpelisib in advanced hormone receptor-positive HER2-negative breast cancer: targeting different nodes of the PI3K/AKT/mTORC1 pathway with different clinical implications

Abstract Background The PI3K/AKT/mTORC1 axis is implicated in hormone receptor-positive HER2-negative metastatic breast cancer (HR+ HER2− mBC) resistance to anti-estrogen treatments. Based on results of the BOLERO-2 trial, the mTORC1 inhibitor everolimus in combination with the steroidal aromatase i...

Full description

Bibliographic Details
Main Authors: Claudio Vernieri, Francesca Corti, Federico Nichetti, Francesca Ligorio, Sara Manglaviti, Emma Zattarin, Carmen G. Rea, Giuseppe Capri, Giulia V. Bianchi, Filippo de Braud
Format: Article
Language:English
Published: BMC 2020-04-01
Series:Breast Cancer Research
Subjects:
Advanced breast cancer
Hormone receptor-positive breast cancer
Endocrine therapy
mTORC1
PI3K
Everolimus
Online Access:http://link.springer.com/article/10.1186/s13058-020-01271-0

Internet

http://link.springer.com/article/10.1186/s13058-020-01271-0

Similar Items